During November-December 2021, we performed a SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji. A total of 539 participants 8-70 years of age were 95.5% (95% CI 93.4%-97.1%) seropositive, indicating high community levels of immunity. Seroprevalence studies can inform public health responses to emerging SARS-CoV-2 variants.
Keywords: COVID-19; Fiji; Pacific Islands; SARS; SARS-CoV-2; antibodies; coronavirus; coronavirus disease; disease outbreak; respiratory infections; seroepidemiologic studies; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.